Clinical Trials
79 trialsNCT05027425 2026-05-06
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
University of Cincinnati
Phase 2 Terminated
NCT05103904 2026-04-24
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
Emory University
Phase 2 Terminated
NCT03727633 2026-03-31
LIDA-BII
University Hospital, Montpellier
Phase 2 Terminated
NCT04327700 2026-03-05
Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
Wake Forest University Health Sciences
Phase 2 Terminated
NCT03785210 2026-02-23
Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT06851104 2026-02-18
A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence
Guangxi Medical University
Phase 2 Terminated
NCT04805788 2025-12-31
Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer
Mayo Clinic
Phase 2 Terminated
NCT05256381 2025-11-17
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
Sotio Biotech Inc.
Phase 2 Terminated
NCT04050462 2025-10-16
Nivolumab Combined With BMS-986253 in HCC Patients
NYU Langone Health
Phase 2 Terminated
NCT05199285 2025-10-03
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab
Academic and Community Cancer Research United
Phase 2 Terminated
NCT05537402 2025-09-24
LOST-B
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT05009979 2025-08-28
18F-DCFPyL PET/CT in Hepatocellular Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT03316872 2025-07-25
Study of Pembrolizumab and Radiotherapy in Liver Cancer
University Health Network, Toronto
Phase 2 Terminated
NCT05563272 2025-07-10
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 2 Terminated
NCT05448677 2025-04-20
ABE-LIVER
University Hospital, Grenoble
Phase 2 Terminated
NCT04629339 2025-03-13
Study of INCB086550 in Select Solid Tumors
Incyte Corporation
Phase 2 Terminated
NCT05137899 2025-03-11
ADVANCE HCC
Ontario Clinical Oncology Group (OCOG)
Phase 2 Terminated
NCT01205828 2025-02-12
ABT-888 and Temozolomide for Liver Cancer
Georgetown University
Phase 2 Terminated
NCT05776875 2025-01-15
Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC
Yale University
Phase 2 Terminated
NCT05653427 2025-01-13
A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma
Janssen Research & Development, LLC
Phase 2 Terminated
NCT03145558 2024-11-22
TATE
Teclison Ltd.
Phase 2 Terminated
NCT01101906 2024-11-20
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
Astellas Pharma Inc
Phase 2 Terminated
NCT00687596 2024-09-19
Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy
Taiho Oncology, Inc.
Phase 2 Terminated
NCT04541173 2024-06-05
Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03591965 2023-07-10
Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects
Antengene Corporation
Phase 2 Terminated
NCT05249569 2023-05-03
Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT03582618 2023-01-10
CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma
TaiRx, Inc.
Phase 2 Terminated
NCT01433016 2022-12-20
OBT for HCC
Meridian Bioscience, Inc.
Phase 2 Terminated
NCT01381211 2022-12-15
TRACE
University Hospital, Ghent
Phase 2 Terminated
NCT03781960 2022-12-14
Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma
Abramson Cancer Center at Penn Medicine
Phase 2 Terminated
NCT02415036 2022-10-17
Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
Delcath Systems Inc.
Phase 2 Terminated
NCT00746590 2022-07-21
Study of Anti-tumour Effects and Safety of Prolarixâ„¢ in Hepatocellular Carcinoma
BTG International Inc.
Phase 2 Terminated
NCT04653389 2022-01-11
Perioperative Therapy for Hepatocellular Carcinoma
Zhejiang University
Phase 2 Terminated
NCT04476329 2021-12-30
ReDos HCC
SC Liver Research Consortium, LLC
Phase 2 Terminated
NCT01032850 2021-06-02
Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT03608878 2021-05-06
Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With GALNT14-rs9679162-non-TT Genotype
Chang Gung Memorial Hospital
Phase 2 Terminated
NCT03303469 2021-02-21
Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: Fluorine18 (18F) Fluoromisonidazole (FMISO) Imaging
University of Alabama at Birmingham
Phase 2 Terminated
NCT03008512 2021-02-04
A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib
Gachon University Gil Medical Center
Phase 2 Terminated
NCT02524119 2021-02-01
LEE001
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT03219372 2021-01-22
Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence
Cedars-Sinai Medical Center
Phase 2 Terminated
NCT03433703 2019-12-06
Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)
Eisai Inc.
Phase 2 Terminated
NCT03318562 2019-07-18
A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC
Effector Therapeutics
Phase 2 Terminated
NCT02950025 2019-04-03
Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies
Washington University School of Medicine
Phase 2 Terminated
NCT02267213 2019-02-26
Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma
Taiwan Liposome Company
Phase 2 Terminated
NCT00832637 2018-06-29
Gem-ox
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00459108 2018-04-19
Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00903396 2017-11-24
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT02549755 2017-11-22
11C-acetate for Treatment Response After Radiotherapy for HCC
Indiana University
Phase 2 Terminated
NCT00003530 2017-11-21
Antineoplaston Therapy in Treating Patients With Primary Liver Cancer
Burzynski Research Institute
Phase 2 Terminated
NCT02821533 2017-08-22
Chemoembolization for Hepatocellular Carcinoma
Chinese University of Hong Kong
Phase 2 Terminated